Back
Bone Biologics Corp (BBLG) Earnings
BBLG Stock Price Chart
BBLG Earnings
Bone Biologics Corp
$1.11
-2.21%
$-0.02
At close: Mar 26, 16:00:00 GMT-4
$1.11
-0.43%
$0
Post-market: Mar 26, 19:17:36 GMT-4
Latest Earnings Results: Q4 '25
Reported: 2026-03-02
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did BBLG's recent EPS compare to expectations?
How did Bone Biologics Corp BBLG's revenue perform in the last quarter?
What is the revenue estimate for Bone Biologics Corp?
What's the earning quality score for Bone Biologics Corp?
When does Bone Biologics Corp report earnings?
What are Bone Biologics Corp's expected earnings?
Did Bone Biologics Corp beat earnings expectations?
Key Stats
Prev.Close
$1.14
Open
$1.13
Day's Range
$1.11 - $1.14
52 week range
$1.11 - $6.75
Volume
12.7K
Avg.Volume
34.9K
Dividend yield
--
EPS (TTM)
-7.30
Market Cap
$1.9M
What is BBLG?
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Features
Resources
© 2026 Finture Development Limited. All rights reserved